MedTrace Logo

A Phase II Study VEPEMB In Patients With Hodgkin's Lymphoma Aged ≥ 60 Years

NCT00079105 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 175

Last updated 2017-03-30

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy, such as vinblastine, cyclophosphamide, procarbazine, prednisolone, etoposide, mitoxantrone, and bleomycin, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more cancer cells.

PURPOSE: This phase II trial is studying how well combination chemotherapy works in treating older patients with previously untreated Hodgkin's lymphoma.

Conditions

Interventions

BIOLOGICAL

bleomycin sulfate

Treatment

DRUG

cyclophosphamide

Treatment

DRUG

etoposide

Treatment

DRUG

mitoxantrone hydrochloride

Treatment

DRUG

prednisolone

Treatment

DRUG

procarbazine hydrochloride

Treatment

DRUG

vinblastine sulfate

Treatment

Sponsors & Collaborators

  • Newcastle-upon-Tyne Hospitals NHS Trust

    lead OTHER

Principal Investigators

  • Stephen J. Proctor, MD · University of Newcastle Upon-Tyne

  • Helen H. Lucraft, MD · Northern Centre for Cancer Treatment at Newcastle General Hospital

  • Katrina M. Wood, MD · Sir James Spence Institute of Child Health at Royal Victoria Infirmary

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • Germany
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00079105 on ClinicalTrials.gov